Completed |
: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
: - Measles
- Mumps
- Rubella
- Va
: 2013-11-08
: - Biological: MMR Bio-Manguinhos
|
Completed |
: Retrospective Clinical Outcome of Parotid Tumor Surgery
: - Parotid Tumors
- Postoperative Complications
: 2013-10-27
|
Completed |
: Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
:
: 2013-06-07
: Biological: MMR (Mumps, Measles and Rubella) MMR (Mumps, Measles and Rubella)
|
Completed |
: Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
:
: 2013-01-21
: Biological: MMR Vaccine Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKlin
|
Withdrawn |
: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
: - Mumps
- Rubella
- Measles
- Va
: 2012-11-28
: - Biological: Priorix-Tetra™
|
Completed |
: A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children
: The Study Focused on the Safety of Attenuated Mumps Vaccine (Human Diploid Cell) Against Mumps in Chinese Adults, Children and Infants.
: 2012-10-22
: - Biological: 3.50±0.25logCCID50/ml
|
Completed |
: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
:
: 2012-09-06
: - Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209
|
Completed |
: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
:
: 2012-06-14
: - Biological: Priorix® Sing
|
Completed |
: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
: - Measles
- Mumps
- Rubella
- Va
: 2012-02-16
: - Biological: MMRV (AMP) Measles
|
Completed |
: The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome
: Parotid Tumor
: 2011-08-10
: Procedure: ADM 29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
|